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Abstract
Background: Bone marrow and adipose tissues are known sources of mesenchymal stem cells (MSCs) in horses;
however, synovial tissues might be a promising alternative. The aim of this study was to evaluate phenotypic
characteristics and differentiation potential of equine MSCs from synovial fluid (SF) and synovial membrane (SM) of
healthy joints (SF-H and SM-H), joints with osteoarthritis (SF-OA and SM-OA) and joints with osteochondritis
dissecans (SF-OCD and SM-OCD) to determine the most suitable synovial source for an allogeneic therapy cell bank.
Methods: Expression of the markers CD90, CD105, CD44, and CD34 in SF-H, SM-H, SF-OA, SM-OA, SF-OCD and
SM-OCD was verified by flow cytometry, and expression of cytokeratin, vimentin, PGP 9.5, PCNA, lysozyme, nanog, and
Oct4 was verified by immunocytochemistry. MSCs were cultured and evaluated for their chondrogenic, osteogenic and
adipogenic differentiation potential. Final quantification of extracellular matrix and mineralized matrix was determined
using AxioVision software. A tumorigenicity test was conducted in Balb-Cnu/nu mice to verify the safety of the MSCs
from these sources.
Results: Cultured cells from SF and SM exhibited fibroblastoid morphology and the ability to adhere to plastic. The
time elapsed between primary culture and the third passage was approximately 73 days for SF-H, 89 days for SF-OCD,
60 days for SF-OA, 68 days for SM-H, 57 days for SM-OCD and 54 days for SM-OA. The doubling time for SF-OCD was
higher than that for other cells at the first passage (P < 0.05). MSCs from synovial tissues showed positive expression of
the markers CD90, CD44, lysozyme, PGP 9.5, PCNA and vimentin and were able to differentiate into chondrogenic
(21 days) and osteogenic (21 days) lineages, and, although poorly, into adipogenic lineages (14 days). The areas
staining positive for extracellular matrix in the SF-H and SM-H groups were larger than those in the SF-OA and SM-OA
groups (P < 0.05). The positive mineralized matrix area in the SF-H group was larger than those in all the other groups
(P < 0.05). The studied cells exhibited no tumorigenic effects.
Conclusions: SF and SM are viable sources of equine MSCs. All sources studied provide suitable MSCs for an allogeneic
therapy cell bank; nevertheless, MSCs from healthy joints may be preferable for cell banking purposes because they
exhibit better chondrogenic differentiation capacity.
Keywords: Equine, Mesenchymal stem cell, Synovial fluid, Synovial membrane, Allogeneic cell bank
* Correspondence: baccarin@usp.br
1Department of Internal Medicine, School of Veterinary Medicine and Animal
Science, University of São Paulo (USP), Avenida Prof. Orlando Marques de
Paiva, 87, 05508-270 São Paulo, SP, Brazil
Full list of author information is available at the end of the article
© 2016 Fülber et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Fülber et al. Stem Cell Research & Therapy  (2016) 7:35 
DOI 10.1186/s13287-016-0294-3
Background
Osteoarticular diseases have received a substantial amount
of scientific attention in recent years, primarily because of
their high prevalence and significant impact on the equine
industry. These diseases irreparably damage articular car-
tilage and negatively influence athletic performance in
horses. Proper treatment has therefore been sought to fa-
cilitate the regeneration of hyaline cartilage and to main-
tain the integrity of its structure. For this purpose, the use
of cellular therapies, including mesenchymal stem cells
(MSCs) from various sources, is a promising tool for the
treatment of osteoarticular disease.
MSCs are characterized by their proliferative ability
and their capacity to differentiate into several mesenchy-
mal lineages, such as osteoblasts, chondrocytes, adipo-
cytes, tenocytes, and myocytes; therefore, they are
classified as multipotent progenitor cells [1–3]. Regen-
erative medicine provides an opportunity to control the
evolution of the disease due to the immunomodulatory,
anti-inflammatory, and tissue regenerative properties of
MSCs. In this context, the use of appropriate popula-
tions appears to be crucial for the successful regener-
ation of damaged articular structures [4].
Regarding horses, MSCs have been obtained from
bone marrow, adipose tissue [5], umbilical cord [6–8],
umbilical cord blood [9], amniotic membrane [10], per-
ipheral blood [11], and recently from synovial fluid (SF)
and synovial membrane (SM) [12, 13].
Although MSCs from synovial tissues have abilities
comparable with those of MSCs from other sources,
they have also been shown to possess high chondrogenic
potential. Additionally, it was inferred that these cells
are already predisposed to differentiate into chondro-
cytes, suggesting that the ancestral microenvironment
directs the “destination” cell upon differentiation [14].
These observations support the hypothesis that these
cells may be prime candidates for the regeneration of
cartilage [15–18]. SM collection can be performed dur-
ing arthroscopy [4, 19–22], and SF can easily be col-
lected through arthrocentesis [23].
Although autologous therapy with MSCs does not re-
sult in any deleterious effects, its use in horses still has
limitations, such as the inability to initiate treatment im-
mediately after arthroscopic diagnosis because the ex-
pansion of MSCs in culture takes 15–26 days [3]. The
treatment of older horses is also limited because there is
an apparent decrease in the abilities of MSCs in this
population. Allogeneic treatment eliminates the long
timeframe that is required to isolate and expand MSCs.
Typically, SF or SM is harvested in cases of osteoarth-
ritis (OA) or osteochondritis dissecans (OCD) during an
arthroscopic procedure that is being conducted for prog-
nostic purposes, and these samples can also be used to
create a cell bank for allogeneic therapy. However, it is
not currently known whether these cell sources exhibit
characteristics similar to those of cells from healthy joint
tissues.
Even in the case of allogeneic therapy, the harvest of
synovial tissue during arthroscopic treatments of joints
with OA or OCD may not the best choice, as SF or SM
could instead be harvested from contralateral healthy
joints. However, there have been few reports of the bio-
logical characterization of equine MSCs from synovial
tissues, so concomitant quantitative and qualitative as-
sessment should therefore be encouraged to identify
these synovial-derived cells and to provide additional in-
formation about them.
Based on this research scenario, we outlined a study
to compare the phenotype, morphology, and multiline-
age differential potential of MSCs from synovial fluid
(SF-MSCs) and from synovial membrane (SM-MSCs) of
horses, using healthy joints, joints with OA, and joints
with OCD. Further, to verify that these SF-MSCs and SM-
MSCs would not differentiate into tumoral cells, we used
a mouse tumorigenicity test.
Methods
Animal ethics
This study was conducted in accordance with the Ethics
Committee on the Use of Animals of the School of Vet-
erinary Medicine and Animal Science of the University
of São Paulo; the protocol number was 2871/2013.
Collection of SF and SM
In this study, a total of 97 joints from 68 horses were ex-
amined. The horses ranged in age from 2 to 10 years, and
no restrictions were placed on breed, sex, or joint. SF and
SM of healthy joints (SF = 14; SM= 16), of joints with
OCD (SF = 21; SM = 16), and of joints with OA (SF = 16;
SM= 11) were collected and used in this experiment.
Horses with joint diseases were examined at the Veter-
inary Hospital of the School of Veterinary Medicine and
Animal Science of the University of São Paulo (FMVZ/
USP), and arthroscopic surgery was indicated for use as
their treatment. In the surgical center, SF and SM sam-
ples were collected from joints with OCD and from
joints with OA. Immediately prior to the procedure, SF
samples were obtained by arthrocentesis using 40 × 10
hypodermic needles. SM samples were collected during
surgery using conventional arthroscopic forceps.
Samples of SF and SM from healthy joints were col-
lected at the beginning of the arthroscopic procedures in
concurrent experiments.
Isolation and culture of SF-derived cells
First, 2 ml of harvested synovial fluid from healthy joints
(SF-H), from joints with OCD (SF-OCD), and from
joints with OA (SF-OA) was suspended in 3 ml of
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Dulbecco’s modified Eagle medium (DMEM; LGC Bio-
technology, Cotia, São Paulo, Brasil) and 10 % (v/v) fetal
bovine serum (FBS; Life Technologies, São Paulo, SP,
Brasil) supplemented with 1 % penicillin/streptomycin,
1 % glutamine (200 mM), 1 % pyruvic acid, and 0.25 %
amphotericin B (Life Technologies, São Paulo, SP, Brasil)
and then plated in a 25 cm2 flask at a cell density of
3.5 × 102/ml (SF-H), 1.91 × 106/ml (SF-OCD), or 1.93 ×
106/ml (SF-OA). Next, the samples were allowed to at-
tach during incubation at 37 °C in a humidified atmos-
phere containing 5 % CO2. On the fourth day, the
medium was aspirated to remove nonadherent cells and
was replaced with fresh medium. The cell cultures were
maintained for sufficient time to monitor cell growth
via inverted microscopy, and fresh medium was pro-
vided every 48 hours until the cells reached 80 %
confluence.
Isolation and culture of SM-derived cells
Harvested synovial membrane from healthy joints (SM-H),
from joints with OCD (SM-OCD), and from joints with
OA (SM-OA) were washed with phosphate-buffered saline
(PBS) containing 1 % penicillin under sterile conditions to
remove debris and blood. Next, approximately 400 mg of
SM were gently debrided with a sterile syringe plunger and
distributed in a 25 cm2 flask with 200 μl of FBS per flask
and were incubated for 20 minutes. After incubation, 5 ml
of supplemented DMEM as already described was added to
each culture, and the culture conditions were maintained
as described for the SF samples.
Trypsinization and doubling time
Cells in all cultures were grown in monolayers under
standard sterile conditions until reaching >80 % conflu-
ence and were then trypsinized. DMEM was removed,
and the cells were washed with 2 ml of PBS. Thereafter,
1 ml of 0.25 % trypsin was added to each flask, and the
samples were incubated at 37 °C for 5 minutes. Subse-
quently, 2 ml of culture medium supplemented with FBS
was added to inactivate the trypsin. The cell suspension
was then aspirated and transferred into a 15 ml conical
tube for centrifugation at 287 × g for 5 minutes to re-
move the trypsin. For each sample, the cell pellet was re-
suspended in 1 ml of supplemented DMEM, and an
aliquot of 10 μl was used for cell counting in a Neubauer
chamber. The remaining cells were transferred into a
75 cm2 flask to which 9 ml of medium was added, and
cells were incubated under the conditions already de-
scribed (considered first passage (P1)). Calculation of the
doubling time (DT) of the mesenchymal cells from SF-
H, SF-OCD, and SF-OA was performed using an algo-
rithm available online [24], accounting for cell number
at P1, second passage (P2), and third passage (P3) during
the exponential growth phase. The formula used by the
online tool was:
DT ¼ t  log2 = logN t = logN0ð Þ
where N0 is the initial number of cells plated, Nt is the
number of cells at the end of the incubation time, and t
is the incubation time in hours. For SMs (SM-H, SM-
OCD, and SM-OA), only the size of the fragment (in
milligrams) was known, rather than the initial numbers
of cells, so the initial cell numbers were estimated based
on the days required for passages (>80 % confluence).
Immunophenotyping characterization
Flow cytometry
Using a FACSCalibur® cytometer (Becton Dickinson, San
Jose, CA, USA) and Cell-Quest software (Becton Dickin-
son, San Jose, CA, USA), phenotypic assessment of SF-H
(n = 14), SF-OCD (n = 21), SF-OA (n = 16), SM-H (n = 16),
SM-OCD (n = 16), and SM-OA (n = 11) was performed
analyzing 5000 cells per group at P3 for all joint conditions.
Mouse anti-rat CD90-phycoerythrin (PE) (clone OX-7;
BD, San Jose, CA, USA), mouse anti-horse CD44-
fluorescein isothiocyanate (FITC) (clone CVS18; AbD Ser-
otec, Oxford, UK), mouse anti-human CD105-RPE (clone
SN6; AbD Serotec, Oxford, UK), and mouse anti-human
CD34-FITC (clone 581; BD) antibodies were used. Anti-
IgG1-PE and anti-IgG1-FITC were used as control isotypes
to calibrate the cytometer. The protocols were performed
according to the manufacturer’s instructions.
Immunocytochemistry
At P3, samples were plated in six-well plates (TPP; Tra-
sadingen, Switzerland), and 3 ml of supplemented
DMEM was added per well. After the cells reached
≥80 % confluence, the DMEM was removed, and the
plates were washed twice with 2 ml of PBS. Next, the
cells were fixed in 4 % paraformaldehyde at 4 °C for
30 minutes. After fixation, the plates were washed again
and then incubated with the following primary anti-
bodies: rabbit anti-human lysozyme (Dako; Carpinteria,
California, USA), rabbit anti-human PGP 9.5 (Spring
Bioscience; Pleasanton, California, USA), rabbit anti-
human Oct4 (Biorbyt; Berkeley, California, USA), goat
anti-human nanog (clone N-17; Santa Cruz Biotechnol-
ogy; Santa Cruz, California, USA), mouse anti-human
vimentin (clone V9; Dako; Carpinteria, California, USA),
mouse anti-human cytokeratin (clones EA-1 and AE3;
Dako; Carpinteria, California, USA), and mouse anti-
human proliferating cell nuclear antigen (PCNA) (clone
PC10; Dako; Carpinteria, California, USA ). The plates
were incubated at 4 °C overnight. Super-Picture polymer
was used to detect the primary antibodies, and the reac-
tions were revealed using diaminobenzidine solution
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(DAB, Sigma, St. Louis, MO, USA) and counterstained
with Harris hematoxylin.
Chondrogenic, osteogenic, and adipogenic cell
differentiation (SF and SM)
The chondrogenic induction was prepared from a solution
containing 2 × 106 cells of pellet cultures during P3, and
cells were cultured in a conical tube with 2 ml of DMEM
for 48 hours. The inductive phase was initiated after the
medium was changed from maintenance medium to a
commercial chondrogenic inducer medium (StemPro
chondrogenesis kit; GIBCO, Carlsbad, California, USA).
The differentiation medium was changed every 48 hours
for a course of 21 days. After this period, the pellets were
washed with PBS and fixed in 4 % paraformaldehyde for
24 hours. To confirm chondrogenic differentiation, histo-
logical slides were prepared, and pellets were stained with
toluidine blue, alcian blue, and hematoxylin and eosin (H
& E; Sigma-Aldrich Corp., St. Louis, MO, USA).
For osteogenic and adipogenic differentiation, cells at P3
were placed in plastic six-well plates at a concentration of
105 cells per well. After the cells had adhered to the plas-
tic, 2 ml of supplemented DMEM was added per well for
a period of 48 hours. Next, the DMEM was replaced with
either the commercial osteogenic inducer medium (Stem-
Pro osteogenesis kit; GIBCO) or the commercial adipo-
genic inducer medium (StemPro adipogenesis kit;
GIBCO), and the medium was changed every 48 hours for
21 or 14 days, respectively. After the differentiation period,
the plates were washed twice with PBS. Osteogenic differ-
entiation was confirmed by positive staining of the extra-
cellular calcium matrix using 2 % Alizarin Red at pH 4.2
(Sigma-Aldrich Corp.). Adipogenic differentiation was
confirmed by the deposition of lipid droplets in the cyto-
plasm using Oil Red O (Sigma-Aldrich Corp.) and staining
of the cell nuclei using H & E. The analysis of control
cells, which received no inducing medium, was conducted
following their culture in DMEM under the same timing
and staining conditions as already described.
Quantification of positive matrix area was performed
using AxioVision LE64 software (Carl Zeiss, Oberko-
chen, Germany). The program analyzed 10 photographs
of each plate (magnification = 10×) and calculated the
area of positive matrix in square micrometers (μm2) for
osteogenic differentiation and square centimeters (cm2)
for chondrogenic differentiation. The intensity of adipo-
genic differentiation was assessed using a scoring system
based on Oil Red O staining (Table 1) [25].
Tumorigenicity test
A tumorigenicity test was performed using nine im-
munosuppressed Balb-Cnu/nu female mice, each approxi-
mately 6 months old and weighing 19–28 g.
Cells that were cultured from SF and SM taken from
healthy and diseased joints (OCD and OA) were grown
in culture to P3 and then injected into dorsal subcutane-
ous tissue in mice at a density of 106 cells per animal.
After 3 months, the mice were sacrificed by intraperito-
neal administration of xylazine, followed by a 10-
minute-long exposure to CO2. Necropsy was performed,
and lung, kidney, liver, subcutaneous tissue, and spleen
samples were collected, weighed, fixed in 10 % formalin,
and sent for histological analysis. The samples were
processed by a paraffin inclusion technique and were
stained with H & E.
Statistical analysis
The data were analyzed using GraphPad Prism 6 (Graph-
Pad Software Inc., San Diego, CA, USA). Significant differ-
ences between groups were determined using one-way
analysis of variance (ANOVA) followed by Dunnett’s test.
All data are expressed as the mean ± standard deviation
(SD), and the level of significance was set at P <0.05.
Results
Cell culture and doubling time
MSCs that were cultured from SF exhibited the capacity
to adhere to plastic after 4–7 days in culture. Mean-
while, MSCs that were derived from SM adhered to the
flasks after 15 days of culture. Both populations had
monolayer growth profiles, morphologically resembled
fibroblasts (Fig. 1), and maintained this appearance after
long-term culture (data not shown).
The doubling times for SF-H, SF-OCD, and SF-OA
were, respectively, 334 ± 64, 585 ± 73, and 333 ± 70 hours
at P1; 144 ± 24, 162 ± 23, and 134 ± 20 hours at P2; and
108 ± 12, 144 ± 13, and 98 ± 8 hours at P3. At P1, one-
way ANOVA revealed a significant difference in doub-
ling time, and the Tukey–Kramer test indicated a signifi-
cant increase in the doubling time of SF-OCD compared
with the SF-H and SF-OA (P <0.05). However, there
were no evident differences at P2 or P3 (Fig. 2).
The timing to reach 80 % confluence during primary
culture varied among the SM samples: 45 days for SM-
H, 38 days for SM-OCD, and 35 days for SM-OA. The
doubling time of SF and the days for passage of SM
could not be compared because the methods for analysis
differed between these conditions. After P1, following
the trypsinization protocol, 80 % confluence was
Table 1 Semiquantitative scoring system used in the evaluation
of adipogenic differentiation
Score % of differentiated cells Size and arrangement of lipid droplets
0 0–5 No droplets
1 >5–50 Isolated and small
2 >50–80 Medium sized
3 >80–100 Predominantly large
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achieved at an average of 11 days for both groups (SF
and SM).
The time that elapsed between primary culture and P3,
when phenotypic characterization and cell differentiation
were performed, was approximately 73 days for SF-H,
89 days for SF-OCD, 60 days for SF-OA, 68 days for
SM-H, 57 days for SM-OCD, and 54 days for SM-OA.
Phenotypic characterization
Flow cytometry
Flow cytometric analysis at P3 indicated that the cells that
were cultured from SF and SM exhibited phenotypic charac-
teristics that were consistent with those of MSCs, and there
were no cells of hematopoietic origin because the cells
exhibited positive expression of the markers CD90 and
CD44 and no expression of the markers CD105 and CD34.
Table 2 presents the average (SD) percentages for each
of the markers from the different sources of MSCs. Sig-
nificantly higher proportions of double-positive cells
Fig. 1 MSCs from synovial tissues during cell culture (P3) showing ≥80 % confluence. SF-H a, SF-OCD b, SF-OA c, SM-H d, SM-OCD e, and SM-OA
f. 100× magnification
Fig. 2 Graph showing the DT (mean ± SD) from SFs (SF-H, SF-OCD,
and SF-OA) during P1, P2, and P3. *P <0.05. P1 first passage, P2 second
passage, P3 third passage, SF-H synovial fluid from healthy joints, SF-OA
synovial fluid from joints with osteoarthritis, SF-OCD synovial fluid from
joints with osteochondritis dissecans
Table 2 Average percentages of MSCs from SF and SM that
exhibited positive or negative expression of CD90, CD44, CD105,
and CD34 markers by flow cytometry
Source Expression
CD90+CD44– CD90–CD44+ CD90–CD44– CD44+CD90+
SF-H 64.9 ± 23.8a 1.18 ± 1.4a 27.3 ± 22.3 6.65 ± 8.86a
SF-OCD 48.3 ± 26.3b 3.98 ± 6b 31.2 ± 24.7 16.5 ± 16.8b
SF-OA 48.1 ± 23b 14.2 ± 25.7c 26.5 ± 19.2 11.2 ± 10.8b
SM-H 66.6 ± 30.1a 1.49 ± 3.2a 29.7 ± 27.6 2.2 ± 2.96a
SM-OCD 40.2 ± 27.2b 2.17 ± 2.6a 48.7 ± 30.1 8.9 ± 18.5a,b
SM-OA 40.3 ± 22.1b 8.56 ± 9.2b 39.9 ± 15.4 11.2 ± 10b
CD105+CD34– CD105–CD34+ CD105–CD34– CD105+CD34+
SF-H 0.25 ± 0.49 0.02 ± 0.04 99.7 ± 0.50 0.03 ± 0.04
SF-OCD 0.22 ± 0.48 0.09 ± 0.29 98.7 ± 3.07 0.96 ± 2.85
SF-OA 0.25 ± 0.50 0.11 ± 0.37 99.3 ± 1.36 0.37 ± 0.82
SM-H 0.28 ± 0.76 0.02 ± 0.03 99.7 ± 0.79 0.02 ± 0.03
SM-OCD 0.36 ± 0.83 0.10 ± 0.27 99.4 ± 1.02 0.17 ± 0.28
SM-OA 0.36 ± 0.54 0.04 ± 0.12 99.4 ± 0.56 0.11 ± 0.14
Data presented as mean ± standard deviation. Different superscript letters in
the same column denote statistically significant differences (P <0.05)
SF-H healthy synovial fluid, SF-OA osteoarthritis synovial fluid, SF-OCD
osteochondritis dissecans synovial fluid, SM-H healthy synovial membrane,
SM-OA osteoarthritis synovial membrane, SM-OCD osteochondritis dissecans
synovial membrane
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(CD44+CD90+) were observed for SF-OCD (16.5 ± 16.8)
and SF-OA (11.2 ± 10.8) than for SF-H (6.65 ± 8.86) (P
<0.05). For SM groups, the same increase was observed
but for SM-OA (11.2 ± 10) compared with SM-OCD
(8.9 ± 18.5) and SM-H (2.2 ± 2.96). Figure 3 shows a dot
plot of the population chosen (gated cell population)
and overlaid histogram analysis representatives from
different synovial source.
Immunocytochemistry
Immunocytochemistry analysis confirmed positive im-
munostaining for lysozyme, PGP 9.5, PCNA, and vimen-
tin in the cells from the SF and SM groups, which
ensured the existence of type A and B synoviocytes, in-
tense cell proliferation, and the presence of MSCs, re-
spectively (Fig. 4). The absence of pluripotent cells and
fibroblasts was confirmed by negative immunostaining
for Oct4, cytokeratin, and nanog.
Differentiation potential
Chondrogenic differentiation was observed after 21 days
in MSCs from both of the groups (SF and SM), at which
point the formation of spherical pellets of hardened ap-
pearance was observed. Chondrogenic potential was
confirmed by alcian blue, toluidine blue (Fig. 5), and H
& E staining, which enabled the identification of an
extracellular matrix rich in proteoglycans and of cells
such as chondrocytes by optical microscopy.
Differences in staining were noticeable in both groups
(SF and SM). Slides containing healthy SF material ex-
hibited much more evident staining and better morph-
ology than slides containing OCD material, which in
Fig. 3 Flow cytometric analysis of the expression of cell surface markers CD90 and CD44 by MSCs. Representative dot plots and histograms
(overlaid) of six different synovial sources: SF-H a, SF-OCD b, SF-OA c, SM-H d, SM-OCD e, and SM-OA f analyzed during the third passage; overlaid
CD44+ cells from SF-H, SF-OCD, and SF-OA g; overlaid CD90+ cells from SF-H, SF-OCD, and SF-OA h; overlaid CD44+ cells from SM-H, SM-OCD, and
SM-OA i; and overlaid CD90+ cells from SM-H, SM-OCD, and SM-OA j (orange line, SF-H and SM-H; red line, SF-OCD and SM-OCD; blue line, SF-OA and
SM-OA). Isotype control antibodies were used (blue dotted line). All sources showed significant expression of mesenchymal markers (CD90 and CD44).
(Color figure online). SSC: side scatter; FSC: forward scatter
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turn exhibited more evident staining than slides contain-
ing OA material.
The SF-H (149 ± 103 cm2) and SM-H (78 ± 7 cm2)
groups showed larger average areas of positive staining
for extracellular matrix than did the SF-OA (32 ±
22 cm2) and SM-OA (43 ± 20 cm2) groups (P <0.05), re-
spectively, but the SF-OCD (49 ± 41 cm2) and SM-OCD
(32 ± 20 cm2) groups appeared similar to the SF-H and
SM-H groups (Fig. 5).
In both groups (SF and SM), osteogenic differentiation
occurred after 21 days of induction. Osteogenic differen-
tiation potential was confirmed by positive staining of
the calcium matrix by Alizarin Red (Fig. 5). The cells in
control culture did not form a calcium matrix, as certi-
fied by negative staining with Alizarin Red.
The average and standard deviation of mineralized
matrix areas for SF-H (1,105,447 ± 1,415,829 μm2) were
larger than for SF-OA (83,765 ± 48,589 μm2), SF-OCD
(295,566 ± 120,472 μm2), SM-H (166,783 ± 193,938 μm2),
SM-OA (141,648 ± 123,734 μm2), and SM-OCD (265,098
± 174,578 μm2) (Fig. 5).
Few cell colonies underwent adipogenic differentiation
by 14 days after induction. This ability appeared to be lim-
ited for this lineage, and the results were similar among
the groups. Adipogenic differentiation was visualized at
small isolated points at the edges of the plates, but cell
death was observed after the induction of differentiation
(i.e., the cells detached from the plates). Adipogenic differ-
entiation potential was confirmed after observation of a
morphology change from fusiform to polygon and by the
deposition of lipid droplets in the cytoplasm, which were
stained by Oil Red O (Fig. 5), and each group reached a
score of 1 (showing <20 % positive cells). The control
population did not undergo the morphological change
and exhibited negative staining.
Tumorigenic potential
None of the mice that received subcutaneous injections
of MSCs from synovial tissues exhibited any changes in
behavior, appetite, body temperature, or local inocula-
tion temperature throughout the experimental period.
A necropsy evaluation revealed no macroscopic changes;
organs and tissue samples were collected (liver, lung, kid-
ney, spleen, and subcutaneous tissue) and were sent for
histological analysis. No changes in tissue characteristics
or cell morphology were observed (Fig. 6). These results
demonstrated that MSCs from synovial tissues are unable
to induce tumor formation and indicate the safety of their
clinical applicability.
Discussion
In this study, cells from synovial tissues were evaluated
as possible sources of MSCs, and their suitability was
assessed based on their expression of surface markers
and their ability to differentiate into various mesenchy-
mal lineages. Subsequently, cells that were cultured from
healthy joints, joints with OA, and joints with OCD
were compared to identify the best candidate for future
clinical applications.
De Bari et al. [4] were the first to isolate MSCs from
synovial tissues. They harvested SM from human pa-
tients with degenerative joint disease and used collage-
nase to extract cells from tissues. Our study was similar
with respect to the aseptic harvesting of cells from dis-
eased (OCD and OA) and healthy joints during surgery.
We observed cell growth in monolayers in all of the
Fig. 4 Representative images of lysozyme, PGP 9.5, PCNA, and vimentin expression in synovial tissues using immunocytochemistry.
Immunocytochemistry of cells from equine SF a–d and SM e–h during their third passage to evaluate the positive expression of the cell surface
markers lysozyme a, e, PGP 9.5 b, f, PCNA c, g, and vimentin d, h. 200× magnification
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samples from SM, although enzymatic digestion with
collagenase was not performed.
In our experiment, the first passage of MSCs from
SM took approximately 15 days, and another 45 days
of incubation time was require for the cells to reach
80 % confluence. This delay could be associated with
the fact that collagenase was not used—as collagenase
has been used in all related studies, in which cell ex-
pansion and cell confluence were observed by the
second week [26, 27].
Fig. 5 Differentiation potential of MSCs from equine SF-H, SF-OCD, SF-OA, SM-H, SM-OCD, and SM-OA. Differentiation of MSCs from SF and SM into
mesenchymal lineages during P3. MSCs after chondrogenic differentiation stained with toluidine blue showing hyaline matrix (blue): SF-H a, SF-OCD b, SF-
OA c, SM-H d, SM-OCD e, and SM-OA f (400× magnification). MSCs stained with Alizarin Red showing matrix calcium formation, confirming the osteogenic
lineage (red): SF-H g, SF-OCD h, SF-OA i, SM-H j, SM-OCD k, and SM-OA l. MSCs showing intracytoplasmic lipid droplets confirming the adipogenic lineage:
SF-Hm, SF-OCD n, SF-OA o, SM-H p, SM-OCD q, and SM-OA r (1000×). Chondrogenic differentiation area s. Osteogenic differentiation area t. Quantification
of positive matrix area was performed using AxioVision LE64 software (Carl Zeiss). The program analyzed 10 photographs of each plate (magnification =
10×) and calculated the area of positive matrix when blue and red stains for chondrogenic and osteogenic differentiation, respectively, were observed.
*P ˂0.05. SF-H synovial fluid from healthy joints, SF-OA synovial fluid from joints with osteoarthritis, SF-OCD synovial fluid from joints with osteochondritis
dissecans, SM-H synovial membrane from healthy joints, SM-OA synovial membrane from joints with osteoarthritis, SM-OCD synovial membrane from joints
with osteochondritis dissecans (Color figure online)AU Query: Confirm Fig 5 caption after editing to style OK
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All of the MSCs evaluated in this study required a long
period of time from primary culture until P3. Typically,
equine MSCs are derived from other sources, such as
bone marrow and adipose tissue, and require 15–25 days
to reach P3 [4]. A relevant result observed was an in-
creased time to reach confluence for the SF-OCD group
at P1 in relation to other synovial sources, but this in-
creased time was not observed for later passages.
All of the cultures from synovial tissues exhibited plas-
tic adherence capacity, monolayer growth, and fibroblas-
toid morphology. The processing was easier for SF cells
than for SM cells. These results are consistent with find-
ings from other studies [17, 26, 28, 29].
The criteria for characterization of MSCs from horses
are based on a marker panel [30] and include several of
the criteria that are used to characterize human MSCs,
as determined by the International Society for Cellular
Therapy [31]. The current study examined cells for the
expression of the surface markers CD90, CD44, CD34,
CD105, Oct4, nanog, vimentin, and cytokeratin to estab-
lish phenotypic expression patterns of SF and SM cells.
Furthermore, the choice of the markers was based on
previous studies on equine MSCs from other sources
that used several of these markers [4, 7, 32, 33].
MSCs from both SF and SM sources exhibited positive
expression for the marker CD90. Higher proportions of
cells showing positive expression for CD90 were found
in SF-H (64.9 %) and SM-H (66.6 %) (P <0.05), suggest-
ing that cells from healthy SF or SM are better sources
of MSCs than are cells from SF-OCD (48.3 %), SF-OA
(48.1 %), SM-OCD (40.2 %), or SM-OA (40.3 %).
A surprisingly low expression rate of the marker CD44
was observed. Similar results have been observed by
Ranera et al. [7], who demonstrated an absence of CD44
expression on cells from bone marrow and adipose tis-
sue. In the present study, it is important to note that
double staining was performed and that competition for
epitopes could have occurred, potentially showing
Fig. 6 Histologic evaluation of tumorigenicity test after subcutaneous injection of P3 cells into Balb-Cnu/nu mice. MSC inoculation a, and subcutaneous
tissue b, kidney c, spleen d, lung e and liver f tissue. The results of tumorigenicity tests in mice showed no compromise of any internal organ, assuring
the applicability of the studied cells. 1000× magnification
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greater expression of CD90 and lower expression of
CD44. Nevertheless, all of the cell populations exhibited
positive expression of CD44, which was more strongly
expressed in the OCD and OA groups than in the
groups from healthy joints (P <0.05).
Interestingly, cells derived from OA exhibited greater
proliferation potential and higher proportions of CD44
+CD90+ double-positive cell expression than cells de-
rived from healthy tissue. According to Kobayashi et al.
[34], the identification of multipotent CD44+/CD90+
stem cells with high proliferative potential suggested that
these cells could provide a basis for continuously self-
renewing cartilage.
Many markers have been frequently tested for use in
horses because of a lack of specific equine antibodies
and the low reactivity levels of markers from other spe-
cies against equine proteins [30]. Therefore, the lack of
CD105 expression observed in the present study may be
related to a low specificity to equine CD105. Addition-
ally, De Schauwer et al. [30] observed large variations in
CD105 expression (0.1–20 %) among umbilical cord
blood samples, and another study on umbilical cord tis-
sue reported negative expression of CD105 [35], possibly
because the antibody that was used did not work for the
cells that were studied.
In the present study, flow cytometry analysis of the
marker CD34 was performed to investigate the presence
of hematopoietic cells in SF and SM cultures. Expression
of CD34 was not found in any of the analyses (0.02 %
SF-H, 0.09 % SF-OCD, 0.11 % SF-OA, 0.02 % SM-H,
0.10 % SM-OCD, and 0.04 % SM-OA). These results are
similar to findings from several previously conducted
studies on human cells in which MSCs from SF and SM
have exhibited either low or no expression of CD34 [36–
39]. Only one study has been published that used equine
MSCs from SF, and it indicated that there was no ex-
pression of CD34 in these cells [12].
Kitamura et al. [40] reported positive immunostaining
of the marker PGP 9.5 in type B synoviocytes, clearly
documenting their distribution in SM. This specificity in
identifying type B synoviocytes was allowed by the com-
parison of immunoreactions in nerve fibers that are dis-
tributed throughout the SM with results obtained from
human brain and horse samples. Type A synoviocytes
are similar to macrophages and are present in SF [41].
The immunocytochemistry data showed conservation
of type A and B synoviocytes in cell cultures from SF
and SM from healthy and diseased joints (OCD and
OA) by positive immunostaining for lysozyme and PGP
9.5. Type A and B synoviocytes were also observed by
Sakaguchi et al. [36] during culture of cells isolated from
synovium; their data suggested that nucleated cells after
isolation or digestion may lose their original profiles and
acquire MSC profiles during the expansion of the MSCs.
Immunocytochemistry analysis mainly showed positive
expression of vimentin and PCNA and an absence of ex-
pression of cytokeratin. These results suggest mesenchy-
mal origin and proliferative abilities for all of the samples.
Additionally, there was an absence of Oct4 expression
in our study. These results were similar to those found in
a study by De Vita et al. [42] that evaluated horse amniotic
fluid; however, they conflicted with results reported in a
study that employed MSCs from goat amniotic fluid [43]
and results from a study that employed MSCs from horse
bone marrow, umbilical cord matrix, and amniotic fluid
[34]. Our results suggest that the studied cells lack pluri-
potency. MSCs from intervascular and perivascular umbil-
ical cord matrix in horses showed positive expression of
Oct4 [35], as did MSCs from human bone marrow and
amniotic membrane [10]. Gao et al. [44] demonstrated
positive expression of Oct4 and nanog in MSCs from hu-
man adipose tissue by immunocytochemistry and reverse
transcription PCR.
MSCs are characterized by an extensive proliferative
ability, as well as by the ability to differentiate in vitro
into various mesenchymal lineages in response to appro-
priate stimuli [4]. In this study, both types of synovial
tissues (SF and SM) were able to differentiate into osteo-
blasts and chondrocytes.
Slides containing healthy SF material exhibited much
more evident staining and better morphology than slides
containing OCD and OA materials, but the average
areas showing positive staining for extracellular matrix
in the SF-H and SM-H groups were only higher than
those of the SF-OA and SM-OA groups. These data
were consistent with the flow cytometric findings show-
ing higher positive expression of CD90 in SF and SM
from healthy joints compared with tissues from OCD or
OA joints. These results suggest that healthy equine SF
and SM represent an attractive source of MSCs for
therapeutic use in osteoarticular diseases.
Currently, several sources have been reported for
obtaining MSCs; however, few studies have compared
synovial tissue with other type of sources. Yoshimura et
al. [45] compared the performance, proliferation cap-
acity, and chondrogenic differentiation potential of
MSCs derived from bone marrow, SM, periosteum, fat,
and muscle. These authors demonstrated a higher chon-
drogenic potential in MSCs from SM due to the in-
creased production of cartilage matrix in relation to
other sources. Similarly, Mochizuki et al. [14] compared
MSCs from SM and adipose tissue (self-renewal and dif-
ferentiation capacity), which also showed a better chon-
drogenic capacity of MSCs derived from SM. It was
inferred that these cells are already predisposed to differ-
entiate into chondrocytes, suggesting that the ancestral
microenvironment directs the “destination” cell upon
differentiation.
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The cells cultured from SF and SM showed little abil-
ity in adipogenic differentiation, as demonstrated by
their limited capacity to produce intracytoplasmic lipid
droplets, in addition to undergoing cell death during the
process of induction. Nevertheless, there were changes
in cell morphology which suggested that they have the
capacity for differentiation into adipocytes.
Regardless of the source of MSCs, the process of adi-
pogenic differentiation in equine cells appears to be
dependent on components found in rabbit serum [25].
Koch et al. [9] and Giovannini et al. [46] found that adi-
pogenic differentiation in equine MSCs which were de-
rived from umbilical cord blood or peripheral blood was
limited when they were induced in standard culture
medium but that the differentiation occurred when the
medium was supplemented with rabbit serum. These ob-
servations may explain the low differentiation rate found
in the current study, as the adipogenic differentiation
was induced using a standard commercial environment
that was not supplemented with rabbit serum.
Tumorigenic analysis showed that MSCs from equine
SF and SM were not able to induce tumors in nude
mice, which was confirmed during necropsy and in
histological slides. This is the first study to demonstrate
that MSCs from equine SF and SM are safe, as they were
unable to cause tumor growth in a laboratory animal
model. Previous studies that have shown the safety and
immunomodulatory characteristics of MSCs from other
sources were based on experiments that were conducted
in vitro and that focused on the suppression of B-
lymphocyte activity [47–50]. The negative results ob-
tained in the tumorigenicity test conducted in this study
further encourage safety of studies in equines.
Regarding the clinical routine, SF is easier to obtain than
SM; furthermore, SF exhibited negative tumorigenicity
and favorable results during phenotypic characterization
and cell differentiation. Based on these results, we con-
sider that the clinical applicability of allogeneic MSCs
from healthy SF must be tested in healthy horses. How-
ever, other authors have observed that allogeneic MSCs
are capable of eliciting antibody responses in vivo (intra-
dermal injection). It has been suggested that such re-
sponses could limit the effectiveness of repeated use of
allogeneic MSCs in a single horse and could also result in
harmful inflammatory responses in recipients [51]. Fur-
ther studies are necessary to analyze whether allogeneic
MSCs injected into equine joint can also be immunogenic.
Conclusions
SF and SM from healthy or diseased joints (OA and
OCD) are feasible sources for harvesting equine MSCs
based on results confirming the phenotypic and multi-
potentiality characteristics of these cells. All sources
studied provide suitable MSCs for an allogeneic therapy
cell bank; nevertheless, MSCs from healthy joints may
be preferable for cell banking purposes because they ex-
hibit better chondrogenic differentiation capacity than
MSCs derived from diseased joints.
The tumorigenicity test showed that MSCs from SF
and SM can be used in clinical trials because they lack
the potential to form teratomas.
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